Weant Kyle A, Smith Kelly M
University of Kentucky Chandler Medical Center, Lexington, KY 40536-0293, USA.
Ann Pharmacother. 2005 Sep;39(9):1522-6. doi: 10.1345/aph.1E554. Epub 2005 Jul 26.
To review the clinical data demonstrating the safety and efficacy of coenzyme Q10 (CoQ10) in heart failure (HF).
Pertinent literature was identified through MEDLINE (1966-January 2005) using the search terms coenzyme Q10, heart failure, antioxidants, and oxidative stress. Only articles written in the English language and evaluating human subjects were used.
HF impairs the ability of the heart to maintain its normal cardiac output. Following an initial insult, cardiac remodeling ensues, resulting in left ventricular dilation and hypertrophy. Oxidative stress is also increased, while CoQ10 levels are decreased in patients with HF. This has led to the hypothesis that CoQ10, an antioxidant, may decrease oxidative stress, impair remodeling, and improve cardiac function.
Large, well-designed studies on this topic are lacking. The limited data from well-designed trials indicate there may be some minor benefits with CoQ10 therapy in ejection fraction and end diastolic volume. CoQ10 therapy has been shown to be relatively safe with a low incidence of adverse effects.
回顾证明辅酶Q10（CoQ10）治疗心力衰竭（HF）安全性和有效性的临床数据。
通过MEDLINE（1966年至2005年1月）检索相关文献，检索词为辅酶Q10、心力衰竭、抗氧化剂和氧化应激。仅使用英文撰写且评估人类受试者的文章。
心力衰竭损害心脏维持正常心输出量的能力。在最初的损伤后，心脏重塑随之发生，导致左心室扩张和肥厚。氧化应激也增加，而心力衰竭患者的CoQ10水平降低。这导致了一种假设，即抗氧化剂CoQ10可能会降低氧化应激、损害重塑并改善心脏功能。
缺乏关于该主题的大型、设计良好的研究。设计良好的试验的有限数据表明，CoQ10治疗在射血分数和舒张末期容积方面可能有一些轻微益处。CoQ10治疗已被证明相对安全，不良反应发生率较低。
